H.C. Wainwright lowered the firm’s price target on Century Therapeutics to $17 from $19 and keeps a Buy rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IPSC:
- Century Therapeutics reports FY22 EPS ($2.27), consensus ($2.32)
- Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
- Century Therapeutics to Present at the AACR Annual Meeting 2023
- Century Therapeutics to Present at Upcoming Investor Conferences
- Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas